$PFE News U.S. stocks fall; Nasdaq 3-day loss worst

New Post Public Reply Private Reply Replies (0) Message Board

Apr 9, 2014 at 7:33 PM

$PFE News

U.S. stocks fall; Nasdaq 3-day loss worst since 2011 4:48 p.m. April 7, 2014 - Victor Reklaitis
Newscast: Wall Street extends recent selloff 4:28 p.m. April 7, 2014 - MarketWatch
Tesla, Facebook seesaw; Questcor surges on deal 3:54 p.m. April 7, 2014 - Ben Eisen
Pfizer shares drop despite positive test for breast-cancer drug 1:03 p.m. April 7, 2014 - blogs.marketwatch.com
Pfizer drops 2.5% to lead Dow decliners 9:35 a.m. April 7, 2014 - William L. Watts
How sector stock funds can make your portfolio whole 7:01 a.m. April 7, 2014 - Jonathan Burton
Best, worst stocks of the $100 billion club: Morgan Stanley 2:03 p.m. March 31, 2014 - blogs.marketwatch.com
Pfizer anti-cholesterol drug meets main study goal 9:28 a.m. March 27, 2014 - MarketWatch.com
Apple looks ready to head higher 3:48 p.m. March 17, 2014 - blogs.marketwatch.com
Apple as the Comeback Kid 1:13 p.m. March 13, 2014 - Mark Hulbert
Mylan to start selling generic Celebrex in May 7:22 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - blogs.marketwatch.com
Pfizer loses ruling on Celebrex patent dispute 2:46 p.m. March 12, 2014 - Russ Britt
Trading resumes on Pfizer shares 2:37 p.m. March 12, 2014 - Russ Britt
Ruling invalidates Pfizer's Celebrex patent 2:36 p.m. March 12, 2014 - Russ Britt
Pfizer obtained reissue patent on Celebrex in 2013 2:35 p.m. March 12, 2014 - Russ Britt
Pfizer plans to appeal ruling on Celebrex judgment 2:31 p.m. March 12, 2014 - Russ Britt
Pfizer loses ruling on Celebrex patent dispute 2:30 p.m. March 12, 2014 - Russ Britt
Pfizer halted 2:15 p.m. March 12, 2014 - Steve Goldstein
S&P 500 extends the break to 'clear skies' territory 10:46 a.m. March 6, 2014 - Michael Ashbaugh

A Favorable Look at Pfizer and Signet 52 min ago - Barrons.com
Pfizer Inc (PFE): Today's Featured Drugs Winner 5:00 p.m. Today - TheStreet.com
Teva to Launch Generic Lovaza - Analyst Blog 4:45 p.m. Today - Zacks.com
3 Stocks Reiterated As A Buy: PFE, GE, MCD 2:44 p.m. Today - TheStreet.com
Dow Today: Pfizer (PFE) Lower 1:00 p.m. Today - TheStreet.com
Top 10 Net Payout Yield Stocks For April 2014 11:19 a.m. Today - Seeking Alpha
Pfizer: It Never Rains, It Pours 7:24 a.m. Today - Seeking Alpha
Wall Street Breakfast: Must-Know News 6:31 a.m. Today - Seeking Alpha
Update on Merck's MK-3475 - Analyst Blog 6:35 p.m. April 8, 2014 - Zacks.com
A Sharp Pullback In Celldex Could Be A Window Of Opportunity 3:41 p.m. April 8, 2014 - Seeking Alpha
Is Buy and Hold Dead? 2:45 p.m. April 8, 2014 - RealMoney.com
The Bottom Is Nowhere in Sight 11:00 a.m. April 8, 2014 - RealMoney.com
Pfizer: Buy the Dip 10:51 a.m. April 8, 2014 - Barrons.com
Use Norway Sovereign Fund's Top Holdings To Your Own Advantage 10:47 a.m. April 8, 2014 - Seeking Alpha
Encouraging Results from Pfizer's Palbociclib - Analyst Blog 10:40 a.m. April 8, 2014 - Zacks.com
Can GlaxoSmithKline Recover? 10:13 a.m. April 8, 2014 - Wall St. Cheat Sheet
Stock Market News for April 08, 2014 - Market News 10:06 a.m. April 8, 2014 - Zacks.com
The 4 Stocks That Slammed the Market 3:44 p.m. April 7, 2014 - 247WallSt.com
Why Pfizer (PFE) Stock Is Down On Monday 2:45 p.m. April 7, 2014 - TheStreet.com
Pfizer Breast-Cancer Drug Scores, But Street Cautious 10:23 a.m. April 7, 2014 - Investors Business Daily

Thyroid Cancer Global Clinical Trials Review, H2, 2013 1:29 p.m. Today - PR Newswire - PRF
Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma 8:00 a.m. Today - PR Newswire - PRF
Diabetic Macular Edema Global Clinical Trials Review, H2, 2013 10:32 a.m. April 8, 2014 - PR Newswire - PRF
NDA Filings, FDA Approvals, Executive Appointments, Ceased Clinical Trials, and Public Offerings - Analyst Notes on Johnson & Johnson, Pfizer, Merck, GSK, and Intercept 8:00 a.m. April 7, 2014 - PR Newswire - PRF
Pfizer's Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer 10:30 a.m. April 6, 2014 - BusinessWire - BZX
AMCP Foundation Launches Initiative to Identify Emerging Medication Management Practices that Can Advance Patient Care and Outcomes; Project Supported by Pfizer 12:38 p.m. April 3, 2014 - PR Newswire - PRF
Exosomes Shine a Light on Alzheimer's Disease and CTE 10:16 a.m. April 3, 2014 - ACCESSWIRE
Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis 8:00 a.m. April 3, 2014 - PR Newswire - PRF
ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool 2:30 p.m. April 1, 2014 - PR Newswire - PRF
LabCentral Announces Sponsorship by Pfizer to Support Life-Science Startup Companies in Cambridge, Massachusetts 8:30 a.m. April 1, 2014 - PR Newswire - PRF
Pfizer Statement on U.S. FDA Approval of Over-the-Counter NexiumÂ® 24HR 6:26 p.m. March 28, 2014 - BusinessWire - BZX
Technical Summary on Active Stocks -- Research on Cisco Systems, Pfizer, Vale, and Advanced Micro Devices 11:31 a.m. March 28, 2014 - PR Newswire - PRF
Positive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analyst Notes on Johnson & Johnson, Merck, Pfizer, Amgen, and Allergan 8:00 a.m. March 28, 2014 - PR Newswire - PRF
In A Subanalysis, The Benefits Of EliquisÂ® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1 8:16 a.m. March 27, 2014 - BusinessWire - BZX
Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study1 8:02 a.m. March 27, 2014 - BusinessWire - BZX
Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPINÂ® In Very Young Children Born Small For Gestational Age 8:01 a.m. March 26, 2014 - BusinessWire - BZX
Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts 5:10 p.m. March 25, 2014 - BusinessWire - BZX
Pfizer Reports Positive Phase 3 Study Outcome Of XALKORIÂ® (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) 8:30 a.m. March 25, 2014 - BusinessWire - BZX
Renaissance Technologies Buys Stake in Pfizer; Yahoo Looks to Profit from Alibaba IPO 12:21 a.m. March 25, 2014 - ACCESSWIRE
Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBRELÂ® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis 11:45 a.m. March 22, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Retirement Dreams Dashed: 61% Withdraw Early

By Olivia Taylor Updated Nov 14, 2026 Category News Views 342

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...